Biological Exposome: Microbiome & Infectious Burden — Exposome
Managing the biological exposome — chronic viral load, gut/oral/skin microbiome composition, parasitic burden, and endotoxin exposure from gut permeability.
Overview
The biological exposome encompasses the cumulative burden of infectious agents, microbial communities, and biological toxins that a person encounters over their lifetime. Key components include: chronic viral burden (CMV seroprevalence ~60-90% in adults, associated with immunosenescence and T-cell exhaustion; EBV latent infection linked to autoimmune risk; H. pylori colonization affecting gastric cancer and cardiovascular risk); gut microbiome composition and diversity (depleted diversity is associated with virtually every chronic disease studied); oral microbiome (periodontal pathogens like P. gingivalis now linked to Alzheimer's via gingipains); skin microbiome disruption from antimicrobial products; parasitic load (often overlooked in developed countries but common in travelers and immigrants); and endotoxin/LPS exposure from increased intestinal permeability ('leaky gut'). A 2024 meta-analysis of 34 studies found that each additional chronic infection is associated with 0.5-2 years of biological age acceleration on epigenetic clocks. The gut microbiome alone contains 100 trillion organisms encoding 3.3 million unique genes (vs. 20,000 human genes), making it arguably the most complex component of the biological exposome.
Indications
- Chronic fatigue with positive CMV or EBV titers
- Autoimmune conditions with possible infectious triggers
- GI dysfunction with suspected dysbiosis or increased intestinal permeability
- Periodontal disease with systemic inflammatory markers
- Post-travel illness or unexplained eosinophilia (parasitic screening)
- Accelerated immunosenescence on immune phenotyping
Mechanism of Action
Latent CMV infection drives clonal expansion of CMV-specific CD8+ T cells, consuming immune 'space' and reducing naive T-cell reserves — contributing to immune aging and reduced vaccine responsiveness
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Comprehensive Stool Analysis (GI-MAP or equivalent) | Single stool sample | Baseline, then post-intervention (3-6 months) | Tests commensal bacteria diversity, pathogenic organisms, parasites (via qPCR), H. pylori, zonulin (intestinal permeability), calprotectin (inflammation), pancreatic elastase |
| Chronic Viral Burden Panel | Blood draw | Baseline | CMV IgG/IgM, EBV panel (VCA IgG/IgM, EBNA, EA), HSV 1/2, HHV-6 — quantitative PCR if reactivation suspected; CMV seropositivity alone is not an indication for treatment |
| Microbiome Diversity Support | High-fiber diet (30+ plant species/week) | Daily dietary practice | American Gut Project: individuals eating 30+ plants/week had significantly greater microbial diversity; fermented foods (6 servings/day in Stanford study) reduced inflammatory markers |
| Oral Microbiome Assessment | Salivary or subgingival sample | Annually (with dental exam) | Tests for P. gingivalis, T. denticola, T. forsythia, A. actinomycetemcomitans — periodontal pathogens with systemic disease links |
Safety & Contraindications
- Do not attempt empiric antiparasitic or antiviral treatment without documented infection — testing before treating
- Aggressive gut microbiome interventions (high-dose probiotics, FMT) should be supervised by GI specialist
- CMV and EBV are lifelong latent infections — 'treating' seropositivity is not possible with current medicine; focus is on immune optimization
- Comprehensive stool testing (GI-MAP, etc.) is a clinical tool — over-interpretation of results without clinical context is common